Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 1
1967 2
1968 1
1969 2
1970 1
1972 1
1974 2
1975 3
1976 4
1977 2
1978 4
1979 1
1980 1
1981 4
1982 6
1983 7
1984 9
1985 5
1986 4
1987 7
1988 6
1989 8
1990 4
1991 8
1992 12
1993 5
1994 11
1995 10
1996 7
1997 8
1998 8
1999 13
2000 9
2001 6
2002 6
2003 9
2004 17
2005 16
2006 11
2007 12
2008 12
2009 9
2010 8
2011 7
2012 8
2013 11
2014 9
2015 10
2016 13
2017 8
2018 7
2019 14
2020 12
2021 12
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

374 results
Results by year
Filters applied: . Clear all
Page 1
Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1.
Jin J, Togo S, Kadoya K, Tulafu M, Namba Y, Iwai M, Watanabe J, Nagahama K, Okabe T, Hidayat M, Kodama Y, Kitamura H, Ogura T, Kitamura N, Ikeo K, Sasaki S, Tominaga S, Takahashi K. Jin J, et al. Among authors: namba y. Respir Res. 2019 Jun 11;20(1):119. doi: 10.1186/s12931-019-1093-z. Respir Res. 2019. PMID: 31185973 Free PMC article.
Advanced lipid technology.
Maeda N, Ikeda K, Matsumoto M, Namba Y. Maeda N, et al. Among authors: namba y. J Liposome Res. 2017 Sep;27(3):221-227. doi: 10.1080/08982104.2016.1224898. Epub 2016 Oct 9. J Liposome Res. 2017. PMID: 27572825 Review.
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).
Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y. Okada M, et al. Among authors: namba y. Clin Cancer Res. 2019 Sep 15;25(18):5485-5492. doi: 10.1158/1078-0432.CCR-19-0103. Epub 2019 Jun 4. Clin Cancer Res. 2019. PMID: 31164373 Free article.
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J. Ueno M, et al. Among authors: namba y. Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621. doi: 10.1016/S2468-1253(19)30086-X. Epub 2019 May 17. Lancet Gastroenterol Hepatol. 2019. PMID: 31109808 Clinical Trial.
[ApoE].
Namba Y. Namba Y. Nihon Rinsho. 2004 Apr;62 Suppl 4:202-5. Nihon Rinsho. 2004. PMID: 15174671 Japanese. No abstract available.
[Bayer ADL].
Umeda Y, Namba Y. Umeda Y, et al. Among authors: namba y. Nihon Rinsho. 2004 Apr;62 Suppl 4:24-30. Nihon Rinsho. 2004. PMID: 15174642 Japanese. No abstract available.
Long-circulating liposomes.
Oku N, Namba Y. Oku N, et al. Among authors: namba y. Crit Rev Ther Drug Carrier Syst. 1994;11(4):231-70. Crit Rev Ther Drug Carrier Syst. 1994. PMID: 7664348 Review.
On soluble mediators of immunologic regulation.
Waksman BH, Namba Y. Waksman BH, et al. Among authors: namba y. Cell Immunol. 1976 Jan;21(1):161-76. doi: 10.1016/0008-8749(76)90337-3. Cell Immunol. 1976. PMID: 55309 Review. No abstract available.
Renal lymphangioma.
Nakai Y, Namba Y, Sugao H. Nakai Y, et al. Among authors: namba y. J Urol. 1999 Aug;162(2):484-5. J Urol. 1999. PMID: 10411064 No abstract available.
374 results